BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36557076)

  • 1. Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.
    Zhang Y; Li R; Gu Y; LiZhu Y; Liu X; Zhang S
    Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557076
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
    PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
    Paajanen J; Laaksonen S; Ilonen I; Wolff H; Husgafvel-Pursiainen K; Kuosma E; Ollila H; Myllärniemi M; Vehmas T
    Lung Cancer; 2018 Feb; 116():73-79. PubMed ID: 29413055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?
    Escalon JG; Harrington KA; Plodkowski AJ; Zheng J; Capanu M; Zauderer MG; Rusch VW; Ginsberg MS
    J Comput Assist Tomogr; 2018; 42(4):601-606. PubMed ID: 29613986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
    Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y; Takuwa T; Miyata Y; Fukuoka K; Hasegawa S; Nakano T; Okada M
    Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features of radiological early malignant pleural mesothelioma with no apparent tumor or pleural thickening.
    Nakamura A; Hashimoto M; Kodama H; Yuki M; Kondo N; Yamakado K; Tsujimura T; Kijima T; Hasegawa S
    Int J Clin Oncol; 2021 Jan; 26(1):95-103. PubMed ID: 32914367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of pretreatment volume-based quantitative
    Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
    Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
    Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
    Lococo F; Rena O; Torricelli F; Filice A; Rapicetta C; Boldorini R; Paci M; Versari A
    Interact Cardiovasc Thorac Surg; 2020 Apr; 30(4):593-596. PubMed ID: 32003806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
    Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
    Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea.
    Kim YK; Kim JS; Lee KW; Yi CA; Goo JM; Jung SH
    Korean J Radiol; 2016; 17(4):545-53. PubMed ID: 27390546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
    Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
    Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience.
    Cimen F; Agackiran Y; Düzgün S; Aloglu M; Senturk A; Atikcan S
    Medicine (Baltimore); 2022 Sep; 101(39):e30711. PubMed ID: 36181042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma.
    Ozmen O; Koyuncu A; Koksal D; Tatci E; Alagoz E; Demirag F; Gokcek A; Arslan N
    Nucl Med Commun; 2016 Jan; 37(1):43-9. PubMed ID: 26440572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Met expression and MET amplification in malignant pleural mesothelioma.
    Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
    Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.